Vor Bio announced that the Phase 3 TELIGAN trial of telitacicept in IgA nephropathy patients in China showed a 55% relative reduction in proteinuria compared to placebo after 39 weeks, with kidney function (eGFR) remaining stable. The trial results, published in The New England Journal of Medicine, highlight telitacicept's potential as a dual BAFF/APRIL therapy for autoimmune diseases. The drug also reduced the risk of significant kidney function decline and showed consistent benefits across patient subgroups. Vor Bio is advancing telitacicept in global trials for other autoimmune diseases, aiming for broader regulatory approvals.
The global automotive microcontrollers market is projected to grow from USD 15.49 billion in 2025 to USD 34.31 billion by 2035, at a CAGR of 8.28%. Growth is fueled by increasing adoption of advanced driver-assistance systems (ADAS), vehicle electrif...
Immuron Limited announced a 6% increase in global sales for FY26, reaching AUD$7.7 million, driven by a 10% rise in Australian sales and significant growth in Canada and the US markets. The growth in Australia is attributed to enhanced digital market...
GRAVITY Co., Ltd. has officially launched Ragnarok: The New World, an open-world MMORPG based on the popular Ragnarok IP, in Southeast Asia on July 16, 2026. The game is available on both Mobile (Google Play and Apple App Store) and PC (official webs...
Zymeworks Inc. will release its second quarter 2026 financial results after market close on August 6, 2026. The company will not hold an earnings call following the release due to its pending acquisition of Theravance Biopharma. This acquisition will...
Global Net Lease, Inc. announced it will release its financial results for the second quarter ending June 30, 2026, on August 5 after the NYSE closes. The company will hold a conference call and webcast on August 6 at 11:00 a.m. ET to discuss the res...
